HUE033133T2 - Metilnaltrexon lipofil sói és azok orális adagolású készítményei - Google Patents

Metilnaltrexon lipofil sói és azok orális adagolású készítményei Download PDF

Info

Publication number
HUE033133T2
HUE033133T2 HUE11157837A HUE11157837A HUE033133T2 HU E033133 T2 HUE033133 T2 HU E033133T2 HU E11157837 A HUE11157837 A HU E11157837A HU E11157837 A HUE11157837 A HU E11157837A HU E033133 T2 HUE033133 T2 HU E033133T2
Authority
HU
Hungary
Prior art keywords
methylnaltrexone
certain embodiments
composition
formulation
opioid
Prior art date
Application number
HUE11157837A
Other languages
English (en)
Inventor
Syed M Shah
Christopher Richard Diorio
Eric C Ehrnsperger
Xu Meng
Kadum A Shareffi
Jonathan Marc Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033133(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HUE033133T2 publication Critical patent/HUE033133T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (7)

  1. Ϊ||ί0|1ί sé! Is azok orális «lagollsá készítményei AzoKtdahn igerts vamk 1, 1-gy (!) általános leplem se
    ahol A" ijeíerrtése .ßgy anvil fii, gyógyásmiüag elfogadható segédanyag anionja, amely segéd*: artyág tartalmas agy Äiete egyenes vagy elágazó, gklkos vagy aeikükus, 4*30 szÉmtomoijIÄ osepmáóh 2> Ax L igénypont $máM. só, Ahol a vagy::-if¥esiÄ.
  2. 3. Αχ 1 igénypont szerinti só, ahol a gy*|gf!páiiá|:ÍÍÍÍgaÉ^tó-.:é%|^ai^áiiÄÄ^·. egy szulfát" í"OS();>*} csoportot,
  3. 4, Az 1-3, igénypontok, bármelyike szerinti ΐό>::ΛόΙ -Ά gyègyâszaÂI tlfèpdhatô sagéd-;:^flig::|^|nax''aiy 4-30 szenatomos aetklikusaltfeospprtek^amely adoft ésothsn ssuhszit-tuálva van, 1> Az 1-3. igénypontok bfeneîyike szerinti 1 .»· .gyÔM^f^lfeliÂiedhaiô'Jéiiày < UAa'maz „es I ' szer,atomos *" ,ιΛΊ e-opottot
  4. 6, .Az 1. igénypont szerinti só, ahol A* jelentése dodecü-szulfók ?. Gyógyászati készítmény orális adagoláshoz, amely tartalmaz, egy szilárd doxisalakot, amely tartalmaz (i) (/f)-A-meül-mdaexont vags annak gyógyászati lag elíbgáiltiÉ sl|4k Ik (U.i amísíiL gyógyászat? lag e) lógatható segóJany^g^|^íi:jpp^pdffiM^tet.f|^)váW a kész nmem, ioîjtfs tömegén u>nutku?ta?va, id-7S *'1> nwna>tségben uriakaae tRVVrociil- yllIlKôari
  5. 8, Aétlgénypónt szerinti gyógyászati készítmény» ahol a üfisg· .élfôgÂÂÄig If-at ami ifik gyúgyásxoübg elfogadható séôl^tÂ;;%lôMp^onp{irt bepez. fi: ¾. I. igénypont szerinti gyógyászati készítmény, ahol m, ionpár akkor képződik. ha a meülnaltrexon vagy annak gyógyászatiéig elfogadható sója és az amüfth gyógyászatílag: êlfe-gadható segédanyag kórülMiil had! imgyobh és körülbelül 4óíí| kisebb pH-értékü oldatban kerül íebddtsra« ló. Λ 7-0, igénypontok bármelyiké szerinti gyögyä^zÄÄzÄdöy» aine|r tartalmaz továbbá egy szétesést elősegítő anyagot is. 1 l, A 7-10, igénypontok bármelyike szerinti gyógyászati készítmény, ahol egy 100? pere tbrdulatszámmal üzemelő keverólapáttai ellátón oldatkmltő berendezésben, bOO ml 0.1 N sósavban, 3/ °€«οη. körülbelül 15 perc alatt a készítmény legalább 50 %-MépÍább t$ Wé. vagy legalább 90 9¾-a oldódik teL mÁWl, igénypontok®^ ahol a készlt^te»d»Í Éá 4 közötti pHzn meghatározott, nvetllbáítrexonm vonatkozó oktanol/vtz megoésiásl. hapy^iö§&amp; legalább (ŐS, legalább ÖJ. legalább 10, legalább 20 vagy legalább 30, 13. À 7-12. igénypontok bármelyike szerinti készítmény*.abit a keszihppsy taridlmaz egy (1) igénypont szerinti vegyületet
    ahol A: jelentése az amílfll gy|gy|szgtll|g ellígndhai© segédanyag anionja. !4i! A 10-13, igénypontok bármelyiké szerinti készítmény, ahol a szétesést elősegítő anyag egy etïerveszeens szétesést elősegíti anyag, például uidrogén-karhooát vagy nátrium*· hidrogén - krehonlí, 15, Λ 7-14. igénypontok bármelyike szerinti készítmény, ahol a készltmlöf §gy tabletta. lii M· 7*1S. igénypontok bárnieiyike szerinti készítmény, ahol a készítmény egy tabletta, amely tartalmaz legalább egy vagy több kötőanyag#!, kdátképaöt nedvesítésben, lobrikÉisl. mm funkcionális buvmmanyapf vagy ηιρ|ρΜ|Ιρ§Ιte ezek kombinációit 17, A 16. igénypont szerinti készítmény, ahol a késauruény amalmaz egy ke lat képzőt, tsiihi például EDTA-t vagyillnalíllíifsipéyáal kaÍdi®^nátmmt-EDTA-t. fl, A. 16. |g|sypotátszdjlití klagltdilhyyahó! á teMtriÄy ltitókán||: péf^· dini mapMnp-szmaráton 19. A 16. -sa^íírégl:! :-?Öfesil !:©! laïlÎââicfeÊÈK ísjg^; példán! aszkmbmsáfik 20. A 7" 19, igénypontok bármelyike szerinti készítmény optoMM. ;^ép Itrápk Ê&amp; vagy több mellékhatásának kezelésére páciensben Âénê'.alkalmse^^. 21. Λ 20. igénypont szerinti készitthiny Ä!ig#»yblt alkalmiéira» áltól a igepkhatások a következők közül % annak kiválasztva: bélmezgás gátoltllg%.p^por-b^mné§^ri,:It^tntá^ pl|í : szlIrskeáéÉi eslkkéní ÍilmoéiÍá> Mliliáfódás,, a gyomét feliááii mözg|Ms: gpMor-béhend&amp;Zfri sziinkter-szükület. tokozott sminlÂibimtôons,. fÿ^M^iMii^^kêoiSgàs-képesség gàkriMga, gyamot; kiütésének gitolíMga, liilÄtolt: igpmprilríté^ fildéges székletürítés, hányiftgér, hápy% bdrpír, puffadás, has! felfúv<|l% vere|tikezéss diszfeí% vrizketegseg és vizdelrekedés.
  6. 22. Eljárás aánloaltrexon-készfttnény előállításira, amely magiban foglalta a kovotkezo lépéseket: nretíinálÉpfönt vagy aondl gyogyászatlkg dfegapali ÉfÉtéá - aniíil, gyé|yásgaíi!á| elfogadható segédanyagként uitrhun-dodeeibszultatot ξ8Π81, valumiut legalább egy széle-ééardisegM anyepi, legalább égy kötőanyagot, legalább egy koláképzp, legalább egy Má~ vMiiMd% és adott esetben legalább «..gy töltőanyagot tartól mazo neches granulátum koszáé* se; és szilárd dèzissgvség kialakítása.
  7. 23. Többrsapus csumng, amet}- *dbb. ij^nypoatok hámsdyike szériát! egysêgdôzis- Mazltmérsv-í tartalmaz.· 24, A '7, igánv'pörg szförídti nyégyászitl kálzltrífesg ataëly a 22, ipdypppi szertptf elfá* fással lelt előállítva.
HUE11157837A 2010-03-11 2011-03-11 Metilnaltrexon lipofil sói és azok orális adagolású készítményei HUE033133T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
HUE033133T2 true HUE033133T2 (hu) 2017-11-28

Family

ID=44148539

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11157837A HUE033133T2 (hu) 2010-03-11 2011-03-11 Metilnaltrexon lipofil sói és azok orális adagolású készítményei

Country Status (32)

Country Link
US (8) US8524276B2 (hu)
EP (2) EP3178472B1 (hu)
JP (4) JP6143409B2 (hu)
KR (2) KR101982482B1 (hu)
CN (2) CN107308125B (hu)
AR (1) AR080491A1 (hu)
AU (1) AU2011224275B2 (hu)
BR (1) BR112012022873B1 (hu)
CA (1) CA2789798C (hu)
CL (1) CL2012002192A1 (hu)
CO (1) CO6630134A2 (hu)
CR (1) CR20120476A (hu)
EA (1) EA029096B1 (hu)
EC (1) ECSP12012208A (hu)
ES (1) ES2623926T3 (hu)
GE (1) GEP201606550B (hu)
GT (1) GT201200247A (hu)
HK (1) HK1245673A1 (hu)
HU (1) HUE033133T2 (hu)
IL (1) IL221452A (hu)
MA (1) MA34146B1 (hu)
MX (2) MX368805B (hu)
MY (1) MY160727A (hu)
NZ (3) NZ703564A (hu)
PE (1) PE20130063A1 (hu)
PL (2) PL3178472T3 (hu)
SG (3) SG10201606618PA (hu)
TN (1) TN2012000392A1 (hu)
TW (2) TWI605814B (hu)
UA (2) UA123856C2 (hu)
WO (1) WO2011112816A1 (hu)
ZA (1) ZA201808498B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2368553T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
EP2164960A2 (en) 2007-05-25 2010-03-24 North Carolina State University Viral nanoparticle cell-targeted delivery platform
NZ703564A (en) 2010-03-11 2016-08-26 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
BR112014014805A2 (pt) * 2011-12-19 2017-06-13 Salix Pharmaceuticals Ltd processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
JP2017519803A (ja) * 2014-07-08 2017-07-20 インシス・ファーマ・インコーポレーテッド 舌下ナロキソンスプレー
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3718404A1 (en) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progession
CN113747882A (zh) * 2019-05-07 2021-12-03 博士医疗爱尔兰有限公司 甲基纳曲酮的液体口服剂量制剂
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
ATE186643T1 (de) 1997-02-14 1999-12-15 Goedecke Ag Stabilisierung von naloxonhydrochlorid
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
DE60238756D1 (de) * 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
WO2002098422A1 (en) 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
JP4814488B2 (ja) 2001-10-18 2011-11-16 ネクター セラピューティックス 重合体共役物オピオイドアンタゴニスト
WO2003048153A1 (en) * 2001-11-29 2003-06-12 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
CN1652752A (zh) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1638607A1 (en) * 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
CA2521369A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
PL2368553T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
CN102935069A (zh) * 2003-07-15 2013-02-20 Pr药品有限公司 控释组合物的制备方法
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
NZ547557A (en) 2003-12-19 2010-07-30 Schering Corp Pharmaceutical compositions containing a cationic A2A receptor antagonist
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
JP5238255B2 (ja) 2004-09-30 2013-07-17 ベクトン・ディキンソン・アンド・カンパニー ガラス製容器内の残留物を削減又は除去するための方法及びそれにしたがって製造されたガラス製容器
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US8091568B2 (en) * 2006-08-16 2012-01-10 Novartis Ag Temporal photo-bleaching of colored lens care solutions and use thereof
WO2008063301A2 (en) * 2006-10-11 2008-05-29 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2010522756A (ja) * 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
ES2540551T3 (es) 2007-03-29 2015-07-10 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
MX2010011727A (es) * 2008-05-07 2010-11-30 Nektar Therapeutics Administracion oral de antagonistas opioides que actuan perifericamente.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
NZ703564A (en) 2010-03-11 2016-08-26 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
NZ703564A (en) 2016-08-26
CR20120476A (es) 2012-11-30
AU2011224275A1 (en) 2012-08-23
JP6143409B2 (ja) 2017-06-07
US20160206612A1 (en) 2016-07-21
JP6429955B2 (ja) 2018-11-28
NZ702826A (en) 2016-08-26
NZ601595A (en) 2015-01-30
WO2011112816A1 (en) 2011-09-15
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
CA2789798C (en) 2020-09-22
US10376505B2 (en) 2019-08-13
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
KR20130010900A (ko) 2013-01-29
CN107308125B (zh) 2021-07-16
US20130330407A1 (en) 2013-12-12
US10507206B2 (en) 2019-12-17
MX2012009125A (es) 2012-09-07
CL2012002192A1 (es) 2012-09-28
BR112012022873A2 (pt) 2016-08-30
JP6647368B2 (ja) 2020-02-14
PL2371357T3 (pl) 2017-09-29
BR112012022873B1 (pt) 2021-09-14
SG10201606618PA (en) 2016-09-29
TWI605814B (zh) 2017-11-21
TN2012000392A1 (en) 2014-01-30
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
EP2371357A1 (en) 2011-10-05
IL221452A0 (en) 2012-10-31
TW201622724A (zh) 2016-07-01
CN102918039B (zh) 2017-06-09
AR080491A1 (es) 2012-04-11
EP2371357B1 (en) 2017-02-01
MY160727A (en) 2017-03-15
US20120070495A1 (en) 2012-03-22
EP3178472B1 (en) 2021-10-27
UA111717C2 (uk) 2016-06-10
US20190117646A1 (en) 2019-04-25
ES2623926T3 (es) 2017-07-12
US8524276B2 (en) 2013-09-03
MX368805B (es) 2019-10-17
SG10201501821RA (en) 2015-05-28
JP2017206553A (ja) 2017-11-24
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
GEP201606550B (en) 2016-10-10
HK1245673A1 (zh) 2018-08-31
US20190117645A1 (en) 2019-04-25
EA201270741A1 (ru) 2013-02-28
CN102918039A (zh) 2013-02-06
JP2011190259A (ja) 2011-09-29
MX349145B (es) 2017-07-14
US20200121673A1 (en) 2020-04-23
US20190314365A1 (en) 2019-10-17
CN107308125A (zh) 2017-11-03
GT201200247A (es) 2013-09-11
EP3178472A1 (en) 2017-06-14
JP2019034958A (ja) 2019-03-07
MA34146B1 (fr) 2013-04-03
SG183133A1 (en) 2012-09-27
US10307417B2 (en) 2019-06-04
CO6630134A2 (es) 2013-03-01
ECSP12012208A (es) 2015-03-31
US9314461B2 (en) 2016-04-19
US20140249171A1 (en) 2014-09-04
JP2016029054A (ja) 2016-03-03
EA029096B1 (ru) 2018-02-28
IL221452A (en) 2017-07-31
PE20130063A1 (es) 2013-02-11
TW201141479A (en) 2011-12-01
KR101913102B1 (ko) 2018-10-31
UA123856C2 (uk) 2021-06-16

Similar Documents

Publication Publication Date Title
US10507206B2 (en) Oral formulations and lipophilic salts of methylnaltrexone
AU2016200133B2 (en) Oral formulations and lipophilic salts of methylnaltrexone
AU2013203559B2 (en) Oral formulations and lipophilic salts of methylnaltrexone